VRC07-523LS: all 22 studies that test it

Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1RecruitingNCT07390955Phase 1
• A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 InfectionNot yet recruitingNCT06987318Phase 1
• Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1RecruitingNCT06517693Phase 1
• Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV RemissionRecruitingNCT02140255Phase 1/2
• Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected WomenCompletedNCT05281510Phase 2Results posted
• A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult ParticipantsCompletedNCT05184452Phase 1Results posted
• Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult ParticipantsCompletedNCT04212091Phase 1Results posted
• Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected PersonsCompletedNCT03803605Phase 1Results posted
• Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1CompletedNCT03739996Phase 2Results posted
• Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult ParticipantsCompletedNCT03735849Phase 1Results posted
• Phase I Study to Evaluate a Human Monoclonal Antibody (MAb) 10E8VLS Administered Alone or Concurrently With MAb VRC07-523LS Via Subcutaneous Injection in Healthy AdultsTerminatedNCT03565315Phase 1Results posted
• Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected AdultsCompletedNCT03387150Phase 1Results posted
• VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy AdultsCompletedNCT03015181Phase 1Results posted
• Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic AdultsCompletedNCT02840474Phase 1Results posted
• Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed InfantsCompletedNCT02256631Phase 1Results posted
• HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies StudyActive, not recruitingNCT07215468Phase 2
• A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIVActive, not recruitingNCT06812494Phase 2
• The Tatelo Plus StudyActive, not recruitingNCT06508749Phase 1/2
• 10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected AdultsActive, not recruitingNCT05890963Phase 1
• Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV RemissionWithdrawnNCT05769569Phase 1
• Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected AdultsCompletedNCT04983030Phase 1/2
• A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected AdultsCompletedNCT03721510Phase 1/2

← VRC07-523LS overview